Free shipping on all orders over $ 500

TAPI-2

Cat. No. M6216

All AbMole products are for research use only, cannot be used for human consumption.

TAPI-2 Structure
Size Price Availability Quantity
1mg USD 200  USD200 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

The hydroxamate-based metalloprotease inhibitor TAPI-2 bounds to hmeprin with inhibition constants IC50 20±10 μM for hmeprin β subunit and 1.5±0.27 nM for hmeprin α subunit. Generally, hmeprin α is inhibited more strongly than the β subunit. Without affecting ADAM17 expression, TAPI-2 dramatically decreases the protein levels of NICD and its downstream target HES-1 in both HCP-1 and HT29 cells. Moreover, treating cells with TAPI-2 significantly decreases the CSC phenotype by ∼50% in both CRC cell lines. The dose-dependent effects of TAPI-2 on the sphere formation and protein levels of NICD and HES-1 confirm that the concentration used (20 μM) is within the effective dose range of TAPI-2 (5–40 μM).

Protocol (for reference only)
Cell Experiment
Cell lines HEK293T cells
Preparation method TAPI-2 is dissolved in DMSO and diluted with appropriate medium before use. All experiments are performed using 20 μM TAPI-2. Cells are cultured with or without TAPI-2 for 48 hours and then seeded at 3,000 cells per well in 96-well plates.
Concentrations 20 μM
Incubation time 48 h
Animal Experiment
Animal models
Formulation
Dosages
Administration
Chemical Information
Molecular Weight 415.53
Formula C19H37N5O5
CAS Number 187034-31-7
Solubility (25°C) 22 mg/mL in DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Raissi AJ, et al. Bioorg Med Chem Lett. Enhanced potency of the metalloprotease inhibitor TAPI-2 by multivalent display.

[2] Akool el-S, et al. Biochem Pharmacol. Cyclosporin A and tacrolimus induce renal Erk1/2 pathway via ROS-induced and metalloproteinase-dependent EGF-receptor signaling.

Related MMP Products
MMP2-IN-1

MMP2-IN-1 is a moderate potenet MMP2 inhibitor with IC50 of 6.8 µM. MMP2-IN-1 exhibits remarkable antiproliferative activity in certain cancer cells by arresting the cell cycle and inducing apoptosis.

MMP-9 Inhibitor I

MMP-9 inhibitor I is a cell-permeable, potent, selective, and reversible inhibitor of MMP-9 (IC50 = 5 nM). MMP-9 inhibitor I also inhibits MMP-1 (IC50 = 1.05 µM) and MMP-13 IC50 = 113 nM) at higher concentrations.

BPHA 

BPHA is a potent and orally active MMP-2, MMP-9 and MMP-14 inhibitor with IC50s of 12 nM, 16 nM and 17 nM, respectively.

ONO-4817 

ONO-4817 is a potent inhibitor of matrix metalloproteinase (MMP).

UK-370106 

UK-370106 is a potent and highly selective MMP-3 (IC50 of 23 nM) and MMP-12 (IC50 of 42 nM) inhibitor with >1200-fold higher potency than MMP-1, MMP-2, MMP-9, and MMP-14, and about 100-fold than MMP-13 and MMP-8.

  Catalog
Abmole Inhibitor Catalog




Keywords: TAPI-2 supplier, MMP, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.